October 15, 2021
Caribbean Cream Ltd. (KREMI) for six months ended August 31, 2021 reported a 16% increase in revenue totalling $1.03 billion compared to $891.40 million in the corresponding period last year. Revenue for the second quarter rose 5% to close at $486.25 million compared to $461.42 million for the comparable quarter of 2020. KREMI sales during the quarter was impacted by tighter COVID-19 measures as Management highlighted, “No movement days imposed on the country in two 3-day periods of Sunday to Tuesday and during the Independence and Emancipation Day holidays, eviscerated a major portion of our sales revenue. Nevertheless, we are thankful for the increase in sales.”
Costs of sales amounted to $673.76 (2020: $581.73 million), this represents an increase of 16% year over year. During the quarter, KREMI experienced higher utility costs, preice increases in key raw materials and an increased foreign exchange rate. Costs associated with logistics due to hemispheric shortfall in shipping containers and a higher importation charges for imported novelties were attributed to the increase in cost of sales. Consequently, gross profit increased by 17% or $51.26 million to $360.93 million compared to $309.67 million for the period ended August 31, 2020. The Company booked gross profit of $153.41 million for the second quarter versus $171.25 million reported for the similar quarter of 2020.
Administrative expenses rose by 32% to close at $249.01 million (2020: $188.27 million), while selling and distribution costs increased by 8% from $28.11 million in 2020 to $30.48 million in the period under review. As a result, operating profit for the six months period amounted to $81.44 million, a 13% decrease relative to $93.29 million reported twelve months earlier. Management noted, “we had planned for higher expenses (mainly for the full-year impact of our Ocho Rios Depot) to sustain our increased sales. The increases are also attributed to:
- Increased electricity due to higher throughput
- Extensive cleaning and sanitization of the facility (Covid-related)
- Staff-related expenditures primarily for COVID testing and transporting factory staff during the lockdowns.
Finance cost fell by 26% year over year, amounting to $11.74 million relative to $9.34 million recorded for the first six months of 2020. Interest income for the period also declined to end at $502,079 relative to the $679,446 for the corresponding six months in the prior year.
Taxation year to date amounted to $8.78 million, a 17% less compared to the $10.58 million charged for the corresponding period last year. As such, KREMI reported net profit of $61.42 million, compared to the $74.05 million for the prior year’s corresponding period. Profit for the quarter amounted to $7.27 million (2020: $46.99 million), down 85% year over year. Consequently, Earnings per Share for the six-month period amounted to $0.16 (2020: $0.20), while the EPS for the quarter totalled $0.02 (2020: $0.12). The trailing twelve months earnings per share amounted to $0.23. The number of shares used in these calculations were 378,568,115 units. Notably, KREMI’s stock price closed the trading period on October 14, 2021 at a price of $6.40 with a corresponding P/E of 27.51 times.
Balance Sheet Highlights:
The company’s assets totalled $1.36 billion (2020: $1.22 billion), $135.15 million more than its value as at August 2020. The increase in assets was largely due to an increase of $101.82 million in ‘Inventories’ to a total of $239.82 million (2020: $138 million). ‘Property, Plant and equipment’ increased by 9% to close the period at $857.69 million compared to the $788.35 million reported in the previous year.
Shareholders’ equity was $869.08 million (2020: $818.28 million), representing a book value per share of $2.30 (2020: $2.16).
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.